Sermorelin vs CJC-1295
Sermorelin and CJC-1295 are both GHRH-analogue research peptides acting on the same receptor, most often compared on their studied half-life and stability.
Sermorelin
Synthetic 29-amino-acid analogue of human GHRH supplied for in-vitro GHRH receptor research.
CJC-1295 (No DAC)
GHRH analogue fragment — studied for growth hormone secretagogue effects.
| Sermorelin | CJC-1295 (No DAC) | |
|---|---|---|
| Class | GHRH analogue (GRF 1-29) | GHRH analogue (modified GRF 1-29) |
| Receptor studied | GHRH receptor | GHRH receptor |
| Research note | Shorter studied half-life | Amino-acid substitutions studied for greater stability |
| Common context | Baseline GHRH-axis models | Stability/half-life comparison models |
Common questions
What is the difference between Sermorelin and CJC-1295 in research?
Both are GHRH analogues acting on the GHRH receptor. CJC-1295 carries amino-acid substitutions studied for greater stability and a longer half-life than Sermorelin, which is the usual focus when the two are compared in research literature.
For research use only. Products are supplied for in-vitro laboratory research and are not for human or veterinary use. Comparison describes research context and mechanism only; it is not guidance for use.